Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
1.780
-0.140 (-7.29%)
At close: Oct 31, 2025, 4:00 PM EDT
1.760
-0.020 (-1.12%)
After-hours: Oct 31, 2025, 4:17 PM EDT
Adagene Employees
Adagene had 138 employees as of December 31, 2024. The number of employees decreased by 36 or -20.69% compared to the previous year.
Employees
138
Change (1Y)
-36
Growth (1Y)
-20.69%
Revenue / Employee
$748
Profits / Employee
-$216,592
Market Cap
83.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138 | -36 | -20.69% |
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | 198 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADAG News
- 12 hours ago - Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 6 weeks ago - Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - GlobeNewsWire
- 2 months ago - Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - GlobeNewsWire
- 2 months ago - Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - GlobeNewsWire
- 2 months ago - Adagene to Participate in Two Investor Conferences in September - GlobeNewsWire
- 2 months ago - Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewsWire
- 4 months ago - Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewsWire